Compare MasTec Inc (MTZ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasTec Inc vs State Street SPDR S&P Biotech ETF — how do they compare? MasTec Inc trades at $283.46 (market cap $21.90B), while State Street SPDR S&P Biotech ETF trades at $159.08. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, MasTec Inc nearer its low. Which is the better fit depends on your goals.
| MTZ | XBI | |
|---|---|---|
Market Cap | $21.90B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $437.51 | $164.28 |
52-Week Low | $172.51 | $86.92 |
Enterprise Value | $24.81B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTZ trades at $282.66, up 5.36% over 24 hours, with a bearish technical signal but strong fundamental momentum. The company reported record Q2 2026 revenue of $4.37 billion, up 23% year-over-year, and raised its full-year outlook, supported by a $21.4 billion backlog and recent acquisition of The Superior Group. Analyst consensus is overwhelmingly bullish with a $439.56 price target, though technical indicators show selling pressure near resistance at $283.
The outlook for MTZ is positive, driven by infrastructure demand and earnings beats, but risks include execution on large projects and debt from recent note issuance. The stock offers growth potential if it can sustain margin expansion and capitalize on its record backlog, though investors should monitor communications segment delays and interest expense impacts.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
